180 related articles for article (PubMed ID: 8833631)
1. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
2. Effect of an alpha-glucosidase inhibitor on glomerular basement membrane anionic sites in streptozotocin induced mildly diabetic rats.
Sato H; Shiina N
Diabetes Res Clin Pract; 1997 Aug; 37(2):91-9. PubMed ID: 9279479
[TBL] [Abstract][Full Text] [Related]
3. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of a small dose of captopril on the reduction of glomerular basement membrane anionic sites in spontaneously hypertensive rats with streptozotocin-induced diabetes.
Isogai S; Kameyama M; Iso K; Yoshino G
J Diabetes Complications; 1998; 12(3):170-5. PubMed ID: 9618073
[TBL] [Abstract][Full Text] [Related]
5. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.
van den Born J; van Kraats AA; Bakker MA; Assmann KJ; Dijkman HB; van der Laak JA; Berden JH
Diabetologia; 1995 Oct; 38(10):1169-75. PubMed ID: 8690168
[TBL] [Abstract][Full Text] [Related]
6. Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats.
Oya M; Hosokawa M; Tsukada H; Fukuda K; Nakamura H; Tsukiyama K; Nagashima K; Fujimoto S; Yamada Y; Seino Y
Diabetes Res Clin Pract; 2003 Nov; 62(2):69-77. PubMed ID: 14581143
[TBL] [Abstract][Full Text] [Related]
7. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
8. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
Reddi AS; Jyothirmayi GN
J Diabetes Complications; 1993; 7(4):233-40. PubMed ID: 8219366
[TBL] [Abstract][Full Text] [Related]
10. Initial ultrastructural changes in pore size and anionic sites of the glomerular basement membrane in streptozotocin-induced diabetic rats and their prevention by insulin treatment.
Isogai S; Mogami K; Shiina N; Yoshino G
Nephron; 1999 Sep; 83(1):53-8. PubMed ID: 10461036
[TBL] [Abstract][Full Text] [Related]
11. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
12. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
Chang WP; Dimitriadis E; Allen T; Dunlop ME; Cooper M; Larkins RG
Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
[TBL] [Abstract][Full Text] [Related]
13. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor.
Osterby R; Gundersen HJ
J Diabet Complications; 1989; 3(3):149-53. PubMed ID: 2528558
[TBL] [Abstract][Full Text] [Related]
14. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A
J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Iso K; Tada H; Kuboki K; Inokuchi T
J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
[TBL] [Abstract][Full Text] [Related]
16. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Takiguchi Y; Wada K; Nakashima M
Eur J Pharmacol; 1992 May; 215(2-3):289-91. PubMed ID: 1396993
[TBL] [Abstract][Full Text] [Related]
17. Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Kanda M; Eto K; Tanabe N; Sugiyama A; Hashimoto K; Ueno A
Jpn J Pharmacol; 1997 Mar; 73(3):221-8. PubMed ID: 9127817
[TBL] [Abstract][Full Text] [Related]
18. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
Yamashita H; Nagai Y; Takamura T; Nohara E; Kobayashi K
Metabolism; 2002 Apr; 51(4):403-8. PubMed ID: 11912544
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
